EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes

Mohsen Khosravi, Domenico De Berardis, Massimo Tusconi

Mental Wellness · 21.04.2026 · 4

DOI: 10.4081/mw.2026.40 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mental Wellness, online erschienen am 21.04.2026. Verfasst von Mohsen Khosravi und 2 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant overall antidepressant effect, with extreme heterogeneity (I2=96.9%) across studies. Notably, the type of control group (active comparator vs. placebo/waitlist) accounted for 98.7% of between-study variance, with waitlist and low-dose comparators producing exaggerated effect sizes. Session frequency was a significant moderator: 2 to 5 psilocybin sessions yielded larger effects, while more intensive protocols attenuated benefit. Neither participant age nor follow-up duration significantly influenced outcomes. Evidence of reporting bias and small-study effects was detected (Egger’s test p=0.012). Sensitivity analyses demonstrated that no single study accounted for the non-significant pooled result. Overall, psilocybin’s antidepressant efficacy appears highly context-dependent—shaped by trial design, comparator, and session structure—rather than universally robust. These findings underscore the need for larger, rigorously controlled trials to clarify psilocybin’s therapeutic role in depression.

Zitieren

APA

Khosravi, M., Berardis, D. D., & Tusconi, M. (2026). The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes. Mental Wellness, 4. https://doi.org/10.4081/mw.2026.40

Vancouver

Khosravi M, Berardis DD, Tusconi M. The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes. Mental Wellness. 2026;4. doi:10.4081/mw.2026.40

BibTeX
@article{Khosravi2026,
  author = {Khosravi, Mohsen and Berardis, Domenico De and Tusconi, Massimo},
  title = {The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes},
  journal = {Mental Wellness},
  year = {2026},
  volume = {4},
  doi = {10.4081/mw.2026.40}
}
Kostenlos starten →